<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034918</url>
  </required_header>
  <id_info>
    <org_study_id>6474IL/0002</org_study_id>
    <nct_id>NCT00034918</nct_id>
  </id_info>
  <brief_title>This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer</brief_title>
  <official_title>An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic
      breast cancer at 2 dose levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>44</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Metastases, Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological and/or cytological confirmation of metastatic breast cancer which is
             refractory to anthracycline, taxane, with or without capecitabine therapies;

          -  WHO performance status 0, 1 or 2 on the day of registration;

          -  Females, aged &gt;= 18 years;

          -  No Gastrointestinal pathology which could affect the bioavailability of ZD6474.

        Exclusion Criteria:

          -  Any evidence of severe or uncontrolled systemic diseases including known cases of
             Hepatitis B or C or human immunodeficiency virus (HIV).

          -  Significant cardiac event (including symptomatic heart failure or unstable angina)
             within 3 months of entry or any cardiac disease that in the opinion of the
             investigator increases risk for ventricular arrhythmia;

          -  History of clinically significant cardiac arrhythmia (multifocal PVCs, bigeminy,
             trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTC
             grade 3) or asymptomatic sustained ventricular tachycardia;

          -  Chronic atrial fibrillation;

          -  Previous history of QT / QTc prolongation with other medication;

          -  Congenital long QT syndrome;

          -  Systemic anti-cancer therapy or other investigational agent within the last 4 weeks (6
             weeks for nitrosoureas, mitomycin C, or suramin);

          -  Currently receiving drugs with known significant 3A4 inhibitory (ie, ketoconazole,
             itraconazole, troleandomycin, erythromycin, diltiazem, verapamil) or stimulatory (ie,
             phenytoin, carbamazepine, barbiturates, rifampicin) effects;

          -  Currently receiving therapeutic doses of warfarin (Coumadin?)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2002</study_first_submitted>
  <study_first_submitted_qc>May 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2002</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

